🎶Nice commentary by @Musjawan@JJCaudell@DavidSherMD et al - caution needed when applying KEYNOTE-689 data especially for CPS <10. ⁉️risks of progression before surgery, toxicity, and cost, with unclear OS benefit.
https://t.co/2tnW92Eo0L
🔥Hot off the press: Patterns of care in de-novo oligo-metastatic and oligo-recurrent head and neck cancers: A Head and Neck Cancer International Group (HNCIG) Survey.
https://t.co/4eGrr6waPr
An @H_N_C_I_G Young Investigator survey initiated by @drmonaliswain and Petr Szturz.
We chose the theme of One Voice for our inaugural year of World Radiotherapy Awareness Day because we want everyone working in the field to join together and speak up for the millions around the world who do not have access to safe, high-quality radiotherapy.
👋Congrats on this comprehensive guideline, a tremendous global effort!
Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas - The Lancet Oncology https://t.co/QghM9OcHiP
Plenary session at #PTCOG63: @SJFrankMD presented extended OS data from the randomized trial of IMPT vs IMRT in H&N cancer.
✅ Proton therapy improved survival
🔍 Not explained by disease progression or G-tube dependence
Looking forward to the full publication of this important trial.
#ProtonTherapy #RadOnc #HNcancer @MDAndersonNews@PTCOG_Official
@henson_md presenting on the @H_N_C_I_G consensus for iENE #HNCS24
This is an important effort by the group @lachiemcd@sueyom that will be incorporated into upcoming revisions for AJCC/UICC TNM staging for HNC.
Watch this space!
Do refer to the Atlas for details.
I defy anyone to read this extraordinarily candid, harrowing & heartbreaking account of the truth of a crippled NHS oncology system & not burn with rage for how this government has decimated the NHS & failed NHS patients.
Please, please read & share 😔
https://t.co/pgLwY9uPlg
But the UK performs noticeably less well than its peers on many important measures of health status and health care outcomes, with a higher avoidable mortality and treatable mortality rates than comparator countries.
This is a stunning failure by the UK’s
public funders to continue to
support NCRI. No more joint planning, no more clinical study groups, etc. Following the demise of England cancer plan this is yet another colossal strategic failure @AggarwalOnc@WHO@UKIGlobalCancer
Over time I’ve tweeted a lot about evidence-based medicine. But oncologists are often in situations with little or no evidence to guide them.
In these situations we go to “first principles”. But what are the first principles? Here’s a thread outlining those I think are key.
Almost everyone has been affected by #cancer, which can devastate the lives of patients and their families.
Our census found the UK is 189 short of the CO consultants needed to provide lifesaving cancer care and is forecast to get even worse.
Read more: https://t.co/btDmuhyIVM
Investigator-initiated trials should receive more recognition by academia. The time & effort that go into getting funding, designing, conducting, & maintaining compliance are enormous. Still they get judged based mostly on clinical results & often wind up in low-impact journals.
The quantitative impact of joint peer review with a specialist radiologist in head and neck cancer radiotherapy planning
https://t.co/252VWkya81
#Radiology#RadOnc#Radiotherapy@DrKevinChiu
Our damning analysis of cancer RWD across 45 drug indications. 78% studies in last decade low quality. Low quality studies more likely to report superior outcomes. Radical overhaul needed by research funders & journals. https://t.co/ox3lR8ZfPM @cspramesh@darioT_@CR_UK